drugset / Trial / NCT07137494
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Phase 1
Recruiting
12 enrolled
Memorial Sloan Kettering Cancer Center
Miltenyi Biomedicine GmbH · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.
Timeline
- Start
- 2025-08-14
- Primary completion
- 2028-08
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 CAR-T cells | Cell therapy | — | — |